Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis

Area of Science:

• Oncology
• Cardiology
• Pharmacology

Background:

• Doxorubicin is a vital chemotherapy drug with known cardiotoxic side effects.
• Understanding the mechanisms of doxorubicin-induced heart damage is crucial for patient safety.

Purpose of the Study:

• To investigate the role of cardiomyocyte apoptosis in acute doxorubicin cardiotoxicity.
• To determine the dose-dependency and temporal effects of doxorubicin on heart cell death.

Main Methods:

• Male Wistar rats received varying doses of doxorubicin (1.25, 2.5, 5 mg/kg).
• Animals were observed and terminated over 7 days to assess myocardial apoptosis and histological changes.
• Apoptosis levels and cytoskeletal alterations were quantified.

Main Results:

• Doxorubicin significantly induced cardiomyocyte apoptosis in a dose-dependent manner within 24-48 hours.
• Repeated doxorubicin injections showed transient apoptosis peaks but no cumulative effect.
• Histological analysis revealed cytoskeletal damage and loss of contractile elements, but no myocyte necrosis.

Conclusions:

• Acute cardiotoxicity from doxorubicin primarily involves cardiomyocyte apoptosis.
• This apoptotic cell death pathway is a significant contributor to myocardial tissue loss.
• Targeting cardiomyocyte apoptosis may offer a strategy to prevent doxorubicin-induced heart damage.